Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma
P. Gunerka, B. Dymek, D. Zdzalik, M. Mroczkiewicz, J. Lipner, B. Stypik, A. Bujak, P. Grygielewicz, O. Musielak, M. Skupinska, J. Hucz-Kalitowska, K. Dubiel, M. Lamparska-Przybysz, M. Wieczorek, A. Stanczak (Lomianki, Lodz, Warsaw, Poland)
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Session: New treatments for cough, asthma, COPD and ILDs
Session type: Poster Discussion
Number: 1509
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Gunerka, B. Dymek, D. Zdzalik, M. Mroczkiewicz, J. Lipner, B. Stypik, A. Bujak, P. Grygielewicz, O. Musielak, M. Skupinska, J. Hucz-Kalitowska, K. Dubiel, M. Lamparska-Przybysz, M. Wieczorek, A. Stanczak (Lomianki, Lodz, Warsaw, Poland). Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma. Eur Respir J 2014; 44: Suppl. 58, 1509
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013
AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
LATE-BREAKING ABSTRACT: Inhibition of RC kinase is a novel therapeutic approach for the treatment of COPD and IPF Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Redefining the asthma treatment paradigm using a locally administered dual PI3Kgd inhibitor Source: International Congress 2016 – New therapies and therapeutic targets Year: 2016